Skip to main content

3 Result(s)

within V. Kansra Remove this filter

and

  1. Article

    Open Access

    Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

    The article ‘‘Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients’’, written by L. van Andel, H. Rosing, Z. ...

    L. van Andel, H. Rosing, Z. Zhang, L. Hughes… in Cancer Chemotherapy and Pharmacology (2018)

    Download PDF (517 KB) View Article

  2. Article

    Open Access

    Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

    Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ov...

    L. van Andel, H. Rosing, Z. Zhang, L. Hughes… in Cancer Chemotherapy and Pharmacology (2018)

    Download PDF (739 KB) View Article

  3. Article

    Open Access

    Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

    Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improv...

    Lotte van Andel, Z. Zhang, S. Lu, V. Kansra, S. Agarwal… in Investigational New Drugs (2017)

    Download PDF (745 KB) View Article